Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Apr;33(4):742-4.
doi: 10.2337/dc09-1600. Epub 2010 Jan 12.

Effect of pioglitazone on energy intake and ghrelin in diabetic patients

Corby K Martin  1 , Alok K Gupta, Steven R Smith, Frank L Greenway, Hongmei Han, George A Bray
Affiliations
Randomized Controlled Trial

Effect of pioglitazone on energy intake and ghrelin in diabetic patients

Corby K Martin et al. Diabetes Care. 2010 Apr.

Abstract

Objective: To measure ghrelin and energy intake in the laboratory after pioglitazone treatment.

Research design and methods: This was a parallel, three-arm study with 51 obese diabetic subjects randomized to either 1) pioglitazone plus a portion-controlled diet (Pio+PC), 2) pioglitazone plus American Diabetes Association (ADA) dietary advice (Pio+ADA), or 3) metformin plus ADA advice (Met+ADA). Energy intake and the suppressive response of a meal on ghrelin were measured at weeks 0 and 16. Mixed models tested if changes from week 0 to 16 differed by group.

Results: The Pio+ADA group had a significantly larger increase (P < 0.05) in energy intake ([adjusted means +/- SE] 207 +/- 53 kcal) compared with the Pio+PC (50 +/- 46 kcal) and Met+ADA (52 +/- 49 kcal) groups. Change in restraint and disinhibition (variables associated with eating behavior) mediated weight change. Ghrelin suppression increased in the Pio+ADA group, which gained weight.

Conclusions: A portion-controlled diet attenuated the increase in energy intake after pioglitazone. Ghrelin responded to weight change not pioglitazone exposure.

Trial registration: ClinicalTrials.gov NCT00219440.

PubMed Disclaimer

References

    1. Forst T, Karagiannis E, Lubben G, Hohberg C, Schondorf T, Dikta G, Drexler M, Morcos M, Danschel W, Borchert M, Pfutzner A. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis 2008;197:311–317 - PubMed
    1. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784–2791 - PubMed
    1. Gupta AK, Bray GA, Greenway FL, Martin CK, Johnson WD, Smith SR. Pioglitazone, but not metformin, reduces liver fat in type-2 diabetes mellitus independent of weight changes. J Diabetes Complications, 2009. [Epub ahead of print] - PMC - PubMed
    1. Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 2005;54:24–32 - PubMed
    1. Gupta AK, Smith SR, Greenway FL, Bray GA. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. Diabetes Obes Metab 2009;11:330–337 - PMC - PubMed

Publication types

Associated data